🔎 Trials Near Me

Akèy › Kansè trakt bilè › Texas › Houston

Etid klinik pou Kansè trakt bilè nan Houston, TX

18 etid pou Kansè trakt bilè ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Ap rekriteFaz 2
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Ap rekriteFaz 2
  • Research Site, Houston
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06219941

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Ap rekriteFaz 3
  • Research Site, Houston
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07221253

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Ap rekriteFaz 1/2
  • University of Texas MD Anderson Cancer Center ( Site 0316), Houston
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06428409

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Ap rekriteFaz 2
  • Research Site, Houston
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT05489211

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Ap rekriteFaz 1
  • Oncology Consultants, Houston
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Ap rekriteFaz 1/2
  • MD Anderson Cancer Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06548412

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Ap rekriteFaz 1/2
  • Avenzo Therapeutics Recruiting Site, Houston
Laj 18 a 75 · Tout sèks · Mizajou Sep 4, 2026 · NCT07038343

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Ap rekriteFaz 1
  • MD Anderson, Houston
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Ap rekriteFaz 3
  • Research Site, Houston
Laj 18 a 99 · Tout sèks · Mizajou Aug 19, 2026 · NCT06467357

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • The University of Texas, MD Anderson Cancer Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Ap rekriteFaz 2
  • University of Texas MD Anderson Cancer Center, Houston
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Ap rekriteFaz 1
  • The University of Texas MD Anderson Cancer Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07458347

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Ap rekriteFaz 1
  • The University of Texas MD Anderson Cancer Center, Houston
Laj 16 ak plis · Tout sèks · Mizajou Jun 2, 2026 · NCT07197554

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • MD Anderson Cancer Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Ap rekriteFaz 2
  • Houston Methodist Hospital Cancer Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT05733598

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Ap rekriteFaz 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2025 · NCT06943521

Etid Kansè trakt bilè nan lòt vil

Lòt etid nan Houston

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.